← Eichor
Study identifier: NCT07219927 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:

Condition: Parkinson Disease  ·  Sponsor: Supernus Pharmaceuticals, Inc.

PhaseN/A
Planned participants120
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease

This description comes directly from the study's public registry record.

Talk to the study team

Mindy Grall, PhD ANP-BC  ·  18663980833  ·  mgrall@supernus.com

Supernus Supernus  ·  18663980833

Always discuss trial participation with your own doctor first.

Locations (5)

Parkinson's Disease and Movement Disorders Center - Orange County (South)Aliso Viejo, California, United StatesRecruiting
Parkinson's Disease and Movement Disorders Center - Orange County (North)Irvine, California, United StatesRecruiting
Parkinson's Research Centers of America - Palo AltoPalo Alto, California, United StatesRecruiting
Parkinson's Disease & Movement Disorders Center of Boca RatonBoca Raton, Florida, United StatesRecruiting
Parkinson's Disease and Movement Disorders Center - Long IslandCommack, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07219927